Cargando…

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma

PURPOSE: This analysis from an observational study of clinical practice describes the impact of febrile neutropenia (FN) on chemotherapy delivery and hospitalizations. METHODS: Adults with diffuse large B-cell lymphoma (DLBCL) scheduled to receive ≥3 cycles of 2- or 3-weekly CHOP with rituximab (R-C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pettengell, Ruth, Johnson, Hans E., Lugtenburg, Pieternella J., Silvestre, Antonio Salar, Dührsen, Ulrich, Rossi, Francesca G., Schwenkglenks, Matthias, Bendall, Kate, Szabo, Zsolt, Jaeger, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271211/ https://www.ncbi.nlm.nih.gov/pubmed/22101611 http://dx.doi.org/10.1007/s00520-011-1306-6

Ejemplares similares

Erratum to: Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
por: Pettengell, Ruth, et al.
Publicado: (2012)

Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practice
por: Weycker, Derek, et al.
Publicado: (2012)

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
por: Pettengell, Ruth, et al.
Publicado: (2008)

Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups
por: Pettengell, Ruth, et al.
Publicado: (2011)

Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP
por: Choi, Yong Won, et al.
Publicado: (2014)

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy
por: Pettengell, R., et al.
Publicado: (2008)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
por: Schwenkglenks, Matthias, et al.
Publicado: (2010)

Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
por: Kim, Do Young, et al.
Publicado: (2022)

Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis
por: Park, Silvia, et al.
Publicado: (2015)

P1139: COMPARISON OF 6XR-CHOP21 VERSUS 6XR-CHOP+2R FOR ADVANCED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA: A PROPENSITY SCORE WEIGHTED POPULATION-BASED ANALYSIS
por: Maas, Carolien, et al.
Publicado: (2023)

Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors
por: Pfeil, Alena M, et al.
Publicado: (2014)

P1520: PROGNOSTIC IMPACT OF FEBRILE NEUTROPENIA AND DOSE INTENSITY OF R-CHOP THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, A SUPPLEMENTARY ANALYSIS OF JCOG0601
por: Yoshida, Isao, et al.
Publicado: (2023)

Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan
por: Yokoyama, Masahiro, et al.
Publicado: (2017)

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
por: Jeong, Seong Hyun, et al.
Publicado: (2022)

Prescribing Empiric Antibiotics for Febrile Neutropenia: Compliance with Institutional Febrile Neutropenia Guidelines
por: Naeem, Doaa, et al.
Publicado: (2018)

Outpatient management of febrile neutropenia in children with cancer
por: Ziino, Ottavio, et al.
Publicado: (2011)

Risk Factors for Febrile Neutropenia during Chemotherapy for HIV-Related Lymphoma
por: Park, Jinyong, et al.
Publicado: (2012)

Developments in the management of febrile neutropenia
por: Pascoe, J
Publicado: (2011)

Febrile neutropenia with bacterial paronychia
por: Hosono, Yuki, et al.
Publicado: (2018)

Febrile Neutropenia in Transplant Recipients
por: Nesher, Lior, et al.
Publicado: (2018)

Febrile Neutropenia in Children with Cancer
por: Paulus, Stéphane, et al.
Publicado: (2008)

Coronaviruses in children with febrile neutropenia
por: Alvares, Paula A., et al.
Publicado: (2013)

Febrile neutropenia in paediatric oncology
por: Davis, Kimberly, et al.
Publicado: (2020)

An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients
por: Ferrández, Maria C., et al.
Publicado: (2023)

Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index
por: Mikhaeel, N. George, et al.
Publicado: (2022)

Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy
por: Hashiguchi, Yasunori, et al.
Publicado: (2015)

An internet-based survey exploring the awareness of febrile neutropenia in patients with malignant lymphoma
por: Takamatsu, Yasushi, et al.
Publicado: (2020)

Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project
por: Wojtukiewicz, Marek, et al.
Publicado: (2014)

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma
por: Gerlier, Laetitia, et al.
Publicado: (2010)

Management of chemotherapy-associated febrile neutropenia
por: Cameron, D
Publicado: (2009)

Clozapine-Induced Febrile Neutropenia and Cellulitis
por: YAYLACI, Selcuk, et al.
Publicado: (2016)

Timely Assessment and Management of Febrile Neutropenia
por: Viale, Pamela Hallquist
Publicado: (2019)

Acute Myelogenous Leukemia and Febrile Neutropenia
por: Herbers, Alexandra, et al.
Publicado: (2009)

How I Treat Febrile Neutropenia
por: Nucci, Marcio
Publicado: (2021)

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
por: Gutiérrez, Antonio, et al.
Publicado: (2015)

Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice
por: Krzemieniecki, K., et al.
Publicado: (2013)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Costs associated with febrile neutropenia in solid tumor and lymphoma patients – an observational study in Singapore
por: Wang, Xiao Jun, et al.
Publicado: (2014)

Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy
por: Wang, Xiao Jun, et al.
Publicado: (2016)

Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland
por: Wojtukiewicz, Marek, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_sb5qghtc844k75ugfn0sjguvto